2019 San Antonio Breast Cancer Symposium (SABCS) 2019 Annual Meeting
Wednesday, December 11th
TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)
Sara M Tolaney, Lorenzo Trippa, William Barry, Jiani Hu, Chau Dang, Denise Yardley, Steven Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Douglas Weckstein, Antonio Wolff, Katherine Reeder-Hayes, Hope Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan Schneider, Merrill Garrett, Kelly Marcom, Kathy Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel Jankowitz, Michelle Demeo, Ann Partridge, Harold Burstein, Eric P. Winer and Ian Krop
Oral Presentation: GS1-05
General Session 1: Wednesday, December 11th from 9:45-10am CT; Hall 3
Thursday, December 12th
Chemotherapy-related amenorrhea (CRA) after Adjuvant Trastuzumab Emtansine (T-DM1) compared to Paclitaxel in combination with Trastuzumab (TH) (TBCRC 033: ATEMPT Trial)
Kathryn J. Ruddy, Lorenzo Trippa, Jiani Hu, William T. Barry, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vincente V. Valero, Meredith G. Faggen, Therese M. Mulvey, Ron Bose, Douglas J. Weckstein, Antonio C. Wolff, Katherine E. Reeder-Hayes, Hope S. Rugo, Bhuvaneswari Ramaswamy, Dan S. Zuckerman, Lowell L. Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit L. Cheng, Frederick M. Briccetti, Bryan P. Schneider, A. Merrill Garrett, P. Kelly Marcom, Kathy S. Albain, Patricia A. DeFusco, Nadine M. Tung, Blair M. Ardman, Rita Nanda, Rachel C. Jankowitz, Michelle K. DeMeo, Harold J. Burstein, Eric P. Winer, Ian E. Krop, Ann H. Partridge and Sara M. Tolaney
Poster: P2-13-02
Poster Session 2: Thursday, December 12th from 7-9am CT; Hall 1
Multiplatform Analysis of Matched Primary and Metastatic Breast Tumors from the AURORA US Network (AURORA RET)
Tari A. King, Minetta C. Liu, Marni B. McClure, Toshinori Hinoue, Benjamin J. Kelly, Chad J. Creighton, Jay Bowen, Kristen Leraas, Robyn T. Burns, Sara Coppens, Salma Rezk, Amy L. Garrett, Justin M. Balko, Joel S. Parker, Ben H. Park, Ian Krop, Carey Anders, Katherine A. Hoadley, Julie Gastier-Foster, Mothaffar F. Rimawi, Rita Nanda, Nancy U. Lin, Claudine Isaacs, P. Kelly Marcom, Anna Maria Storniolo, Fergus J. Couch, Elaine R. Mardis, Adrian V. Lee, Uma Chandran, Peter W. Laird, Susan G. Hilsenbeck, Larry Norton, Andrea L. Richardson, W. Fraser Symmans, Lisa A. Carey, Antonio C. Wolff, Nancy E. Davidson, Charles M. Perou
Oral Presentation: GS3-08
General Session 3: Thursday, December 12th from 11:15-11:30am CT; Hall 3
Pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease: Translational Breast Cancer Research Consortium (TBCRC 044)
Neelima Vidula, Rita Nanda, Kathy Miller, Vandana Abramson, Paula Pohlmann, Adam Brufsky, Ben Park, Minetta Liu, Andrei Goga, and Hope S. Rugo
Poster: OT2-04-05
Poster Session OT2: Thursday, December 12th from 5-7pm CT; Hall 1
TBCRC 049: A Phase II Non-Randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Rashmi K Murthy, Barbara J O'Brien, Ken R Hess, Nick Navin, Jason Johnson, Maria Gule-Monroe, Jose P Leone, Jennifer Specht, Michelle Melisko, Aki Morikawa, Anna M Storniolo, Adam Brufsky, Paula R Pohlmann, Deric M Park, Ben H Park, Ian Krop, Nancy U Lin, Antonio Wolff, Andres Forerro-Torres and Erica Stringer-Reasor
Poster: OT2-01-02
Poster Session OT2: Thursday, December 12th from 5-7pm CT; Hall 1
Friday, December 13th
The Genomic Landscape of Male Breast Cancers using the Oncomine Comprehensive Assay for Actionable Mutations (TBCRC 029)
Jane Bayani, Coralie Poncet, Cheryl Crozier, Quang M Trinh, Megan Hopkins, Aime Lambert Uwimana , Tammy Piper, Carrie Cunningham, Monika Sobol, Stefan Aebi, Kim Benstead, Oliver Bogler, Lissandra Dal Lago, Judith Fraser, Florentine Hilbers, Ingrid Hedenfalk, Larissa Korde, Barbro Linderholm, John Martens, Lavinia Middleton, Melissa Murray, Catherine Kelly, Cecilia Nilsson, Monika Nowaczyk, Stephanie Peeters, Aleksandra Peric, Peggy Porter, Carolien Schröder, Isabel T. Rubio, Kathryn J. Ruddy, Christi van Asperen, Danielle Van Den Weyngaert, Carolien HM van Deurzen, Elise van Leeuwen-Stok, Joanna Vermeij, Eric Winer, Lincoln Stein, Sharon H. Giordano, Fatima Cardoso, John MS Bartlett
Poster: P4-10-03
Poster Session 4: Friday, December 13th from 7-9am CT; Hall 1
Patient Reported Outcomes from the Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel + Trastuzumab (TH) (ATEMPT) Trial (TBCRC 033)
Ann Partridge, Yue Zheng, Shoshana Rosenberg, Richard Gelber, Shari Gelber, William Barry, Chau Dang, Denise Yardley, Steven Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Douglas Weckstein, Antonio Wolff, Katherine Reeder-Hayes, Hope Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan Schneider, Merrill Garrett, P. Kelly Marcom, Kathy Albain, Patricia Defusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel Jankowitz, Michelle DeMeo, Harold Burstein, Eric P. Winer, Ian Krop and Sara Tolaney
Spotlight Discussion: PD10-02
Spotlight Session 10: Friday, December 13th from 7-9am CT; Stars at Night Ballroom 3 & 4
Cisplatin versus doxorubicin/ cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCA carriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC 031)
Nadine Tung, Banu Arun, Erin Hofstatter, Michele R. Hacker, Deborah L Toppmeyer, Steven J Isakoff, Virginia Borges, Robert D Legare, Claudine Isaacs, Antonio C. Wolff, Paul Kelly Marcom, Erica L Mayer, Paulina B Lange, Andrew J Goss, Ian E Krop, Eric P Winer, Stuart J Schnitt, Judy E Garber
Oral Presentation: GS6-03
General Session 6: Friday, December 13th from 3:45-4pm CT; Hall 3
Saturday, December 14th
TBCRC 040: Pathologic Response Evaluation and Detection In Circulating Tumor DNA (PREDICT DNA): Initial results piloting a tissue-biopsy independent method of identifying and monitoring tumor-specific mutations in early stage breast cancer
Natasha Hunter, Heather Parsons, Alexander Sherry, Daniel Shinn, Dong Ho Shin, Alex Cole, Giovanni Cragnotti, Taylor Groginski, Margaret Leathers, Andrea L Richardson, Pedram Argani, Antonio Wolff, Leslie Cope, Dan Edelstein, Frank Holtrup, Hillary Sloane, Bapsi Chakravarthy, Vered Stearns, Ben H Park
Poster: P6-10-05
Poster Session 6: Saturday, December 14th from 7-9am CT; Hall 1
American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
TBCRC 030: A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in TNBC—Evaluating the Homologous Recombination Deficiency (HRD) Biomarker
Erica L. Mayer, Vandana Gupta Abramson, Rachel Catherine Jankowitz, Carla Isadora Falkson, Paul Kelly Marcom, Tiffany A. Traina, Lisa A. Carey, Mothaffar F. Rimawi, Jennifer M. Specht, Kathy Miller, Vered Stearns, Charles M. Perou, Andrea L. Richardson, Nadine M. Tung, William Thomas Barry, Zhenying Tan-Wasielewski, Kirsten Timms, Anne-Renee Hartman, Antonio C. Wolff, Eric P. Winer
Abstract: #507
Oral Abstract Session: Monday, June 3rd from 9:45am-12:45pm CT; Hall D2 (presented 11:57am-12:09pm CT)
American Association for Cancer Research (AACR) 2019 Annual Meeting
Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive (HR+) Metastatic Breast Cancer (MBC) with Prior Chemotherapy for Advanced Disease (TBCRC 035) A Phase II Study with Pharmacodynamics Markers
Hope S Rugo, Erica L Mayer, Anna Marie Storniolo, Claudine Isaacs, Ingrid Mayer, Vered Stearns, Rita Nanda, Julie Nangia, Chiara Wabl, Michelle Melisko, Alona Muzikansky, Bose Kochupurakkal, Ben Park, Antonio C Wolff, and Geoff I Shapiro
Talk: CT128
Session: Clinical Trials Minisymposium 2: The Next Generation of Clinical Trials in Molecularly Driven Therapy
Oral Presentation: Monday, April 1st from 3:20-3:35pm ET; Marcus Auditorium- Building A
2019 Publications
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer (TBCRC 006)
Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, Fuqua SAW, Prat A, Hilsenbeck SG, Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, Rimawi MF, Schiff R
Annals of Oncology, 2019 Mar; PMID: 30903140
Pre- and Post-operative Neratinib for HER2-Positive Breast Cancer Brain Metastases : Translational Breast Cancer Research Consortium 022 (TBCRC 022)
Rachel A. Freedman; Rebecca S. Gelman; Nathalie Y. R. Agar; Ian Dunn; Carey K. Anders; Catherine H. Van Poznak; Michelle E. Melisko; Kelly Silvestri; Christine M. Cotter; Kathryn P. Componeschi, Juan M. Marte, Roisin M. Connolly; Beverly Moy; Kimberly L. Blackwell; Shannon L. Puhalla; Nuhad Ibrahim; Timothy J. Moynihan; Julie Nangia; Nadine Tung; Robyn Burns; Mothaffar F. Rimawi; Ian E. Krop; Antonio C. Wolff; Eric P. Winer; Nancy U. Lin
Clinical Breast Cancer, 2019 Aug, PMID: 31558424
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU
J Clin Oncol, 2019 May; PMID: 30860945
TBCRC 023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab (L+T) With Endocrine Therapy and Without Chemotherapy, for 12 vs. 24 Weeks in Patients with HER2-positive Breast Cancer
Mothaffar F. Rimawi, Polly A. Niravath , Tao Wang , Brent Rexer , Andres Forero , Antonio C. Wolff , Rita Nanda , Anna M. Storniolo , Ian E. Krop , Matthew P. Goetz, Julie R. Nangia , Sao Jiralerspong , Anne C. Pavlick , Carmine De Angelis , Carolina Gutierrez , Rachel Schiff , Susan G. Hilsenbeck , and C. Kent Osborne
Clin Cancer Res, 2019 Oct; PMID: 31662331
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade (TBCRC 023)
Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF
J. Natl Cancer Inst, 2019 Apr; PMID: 31037288
TBCRC 026: Phase II Trial Correlating Standardized Uptake Value on FDG PET/CT with Pathologic Complete Response to Pertuzumab and Trastuzumab in HER2-positive Breast Cancer
Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey L, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V
J Clin Oncol, 2019 Mar; PMID 30721110
Patient-reported Outcomes in the Translational Breast Cancer Research Consortium
Deborah Bowen, Eileen Shinn, Sophie Gregrowski, Gretchen Kimmick, Laura Dominici, Elizabeth Frank, Karen Smith, Gabrielle Rocque, Kathryn J. Ruddy, Teri Pollastro, Michelle Melisko, Tarah Ballinger, Oluwadamilola Fayanju, Antonio C. Wolff
Cancer, 2019Nov; PMID: 31743427